Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Pulmonary Hypertension
94%
Hematologic Malignancy
90%
Chimeric Antigen Receptor T-Cell
86%
Intensive Care
74%
Malignant Neoplasm
71%
Chimeric Antigen Receptor
70%
Hematopoietic Stem Cell Transplantation
70%
Cytokine Release Syndrome
63%
Hospital Mortality
58%
Sepsis
50%
Intensive Care Unit
50%
Bloodstream Infection
49%
Odds Ratio
49%
Interstitial Lung Disease
47%
Septic Shock
47%
COVID-19
47%
Toxicity and Intoxication
45%
Effector Cell
41%
Infection
37%
Deterioration
36%
Cell Therapy
35%
Respiratory Failure
33%
Oncology
33%
Clinician
31%
Critical Illness
31%
Pathogen
29%
Severe Acute Respiratory Syndrome Coronavirus 2
28%
Chimeric Antigen Receptor T-Cell Immunotherapy
28%
Immunotherapy
26%
Fluid Balance
26%
Antibiotic Therapy
26%
Artificial Respiration
26%
Retrospective Cohort Study
24%
Emphysema
23%
Gestational Hypertension
23%
Survival Analysis
23%
Chronic Obstructive Pulmonary Disease
23%
Treprostinil
23%
Silo-Filler's Disease
23%
Bone Marrow Transplantation
23%
Interleukin 6
23%
Acute Respiratory Distress Syndrome
23%
Graft Versus Host Reaction
23%
Stenotrophomonas maltophilia
23%
Receptor Blocking Agent
23%
Secondary Infection
23%
Acute Respiratory Failure
23%
Interleukin 6 Receptor
23%
Patient Registry
23%
Heart Function
23%
Keyphrases
Pulmonary Arterial Hypertension
100%
Chimeric Antigen Receptor T Cells (CAR-T)
86%
Hematological Malignancies
72%
Cytokine Release Syndrome
63%
Hospital Mortality
57%
Critically Ill Patients
56%
Pulmonary Hypertension
54%
Interstitial Lung Disease
50%
Septic Shock
47%
Inhaled Treprostinil
47%
Bloodstream Infection
47%
Selexipag
47%
Critical Care
41%
Intensive Care Unit
40%
Odds Ratio
39%
Patients with Cancer
37%
Appropriate Antibiotics
36%
Critical Illness
35%
Critical Care Management
35%
Respiratory Failure
33%
Improved Outcomes
32%
Clinical Deterioration
32%
Chimeric Antigen Receptor T-cell Therapy
31%
Cell-Associated
30%
Neurotoxicity
29%
Mechanical Ventilation
28%
Confidence Interval
28%
COVID-19
28%
Intensivist
27%
Fluid Balance
26%
Sepsis
26%
Adjusted Odds Ratio
26%
Clinical Outcomes
25%
Clinical Patients
25%
Interleukin-6 Levels
23%
Pulmonary Graft-versus-host Disease
23%
Emphysema
23%
Acute Respiratory Failure
23%
Toxicity Management
23%
Mechanically Ventilated Patients
23%
Interleukin-6 Inhibitors
23%
Hypertensive Disorders of Pregnancy
23%
Tyvaso
23%
Dry Powder Inhaler
23%
Lung Disease
23%
Infection Prediction
23%
Interleukin-6
23%
Secondary Infection
23%
Acute Respiratory Distress Syndrome
23%
Bone Marrow Transplantation
23%
Pharmacology, Toxicology and Pharmaceutical Science
Pulmonary Hypertension
80%
Treprostinil
70%
Chimeric Antigen Receptor
70%
Malignant Neoplasm
55%
Cytokine Release Syndrome
47%
Selexipag
47%
Hematologic Malignancy
47%
Hospital Mortality
33%
Prostacyclin
32%
Respiratory Failure
32%
Infection
30%
Toxicity and Intoxication
29%
Infectious Agent
29%
SARS Coronavirus
28%
Immunotherapy
26%
Diseases
26%
Bloodstream Infection
26%
Interstitial Lung Disease
25%
Deterioration
25%
Interleukin 6 Receptor
23%
Secondary Infection
23%
Coronavirinae
23%
Dry Powder Inhaler
23%
Adult Respiratory Distress Syndrome
23%
Interleukin 6
23%
Receptor Blocking Agent
23%
Septic Shock
23%
Macrolide
23%
Survival Rate
23%
Tolerability
23%
Sepsis
23%
Health Care Associated Pneumonia
23%
Macitentan
23%
Antidepressant
23%
Serotonin Reuptake Inhibitor
23%
Viral Respiratory Tract Infection
23%
Observational Study
23%
CAR T-Cell Therapy
23%
Cohort Study
20%
Side Effect
16%
Adverse Event
16%
Antibiotics
15%
Bleeding
15%
Community Acquired Pneumonia
14%
Thrombocytopenia
13%
Hypertensive Factor
12%
Human Respiratory Syncytial Virus
11%
Enterovirus
11%
Overall Survival
11%
Neurotoxicity
11%
